<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">CRCM</journal-id><journal-title-group><journal-title>Case Reports in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2325-7075</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/crcm.2022.113011</article-id><article-id pub-id-type="publisher-id">CRCM-115971</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  An Extensively Drug Resistant &lt;i&gt;Acinetobacter baumannii&lt;/i&gt; from Soft Tissue Isolated in a Hospital in Senegal
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cheikh</surname><given-names>Fall</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ousmane</surname><given-names>Sow</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fatim</surname><given-names>P. Ly</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Boly</surname><given-names>Diop</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bissoume</surname><given-names>Sambe-Ba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yakhya</surname><given-names>Dieye</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Pole de Microbiologie, Institut Pasteur de Dakar, Dakar, Senegal</addr-line></aff><aff id="aff2"><addr-line>Direction de la Prévention, Ministère de la Santé et de L’action Sociale, Dakar, Senegal</addr-line></aff><pub-date pub-type="epub"><day>03</day><month>03</month><year>2022</year></pub-date><volume>11</volume><issue>03</issue><fpage>72</fpage><lpage>78</lpage><history><date date-type="received"><day>14,</day>	<month>January</month>	<year>2022</year></date><date date-type="rev-recd"><day>15,</day>	<month>March</month>	<year>2022</year>	</date><date date-type="accepted"><day>18,</day>	<month>March</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Emerging and rapidly spreading multidrug resistant bacteria constitute a rising public health concern worldwide. 
  <em>Acinetobacter baumannii</em> is one of these bacteria that cause different infections including pneumonia, bacteremia, meningitis, soft-tissue, and urinary tract infections, and are associated with high mortality and economic burden. We present a case of a 43-year-old woman, admitted at the department of orthopedics, regional hospital of Ourossogui, North-East of Senegal for soft-tissue injuries. Initially diagnosed with 
  <em>Yersinia pestis</em> infection, the patient was well managed before being released. Supplementary sampling for confirmatory tests allowed the detection of an extensively drug-resistant 
  <em>Acinetobacter baumannii </em>clone.
 
</p></abstract><kwd-group><kwd>&lt;i&gt;Acinetobacter baumannii&lt;/i&gt;</kwd><kwd> Extensively Drug Resistance</kwd><kwd> Soft-Tissue</kwd><kwd> Senegal</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Acinetobacter baumannii has become a leading cause of nosocomial infections, especially in patients in intensive care units (ICUs). A. baumannii clones are often multidrug-resistant (MDR), leaving limited options for antibiotic treatment [<xref ref-type="bibr" rid="scirp.115971-ref1">1</xref>]. The World Health Organization (WHO) recently ranked carbapenem-resistant A. baumannii as the most critical bacterial pathogen for public health [<xref ref-type="bibr" rid="scirp.115971-ref2">2</xref>]. Invasive procedures and patients’ exposure to certain antimicrobials are risk factors for colonization and infections by MDR A. baumannii. Moreover, cross-transmission among hospitalized patients is favored by poor adherence to hand hygiene practices and by repeated contact with contaminated environments [<xref ref-type="bibr" rid="scirp.115971-ref3">3</xref>]. Despite the increase incidence of MDR A. baumannii in many parts of the world, data from sub-Saharan Africa are scarce. We present a case of an extensively drug-resistant A. baumannii isolated from the soft tissues of a 43-year-old woman.</p></sec><sec id="s2"><title>2. Case Presentation</title><p>This case represented a 43-year-old woman living in Ourossogui, North-East of Senegal, who was admitted on May 18<sup>th</sup>, 2021 to the orthopedic department of the regional hospital as shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. The motif of consultation was an oozing wound on the back of the sole of her right foot and the patient attested not having any particular pathological history, except hypertension. During the medical examination, she said that signs began in September 2020 with a blackish point with an oozing clear fluid. About two months later, her situation deteriorated such that she could not stand on her feet and developed a fever. She visited a peripheral healthcare facility in November 2020, where she received aseptic cleaning and an antibiotic treatment that was presumed to be cotrimoxazole. With a slight improvement, she resumed her daily activities until six months later when her situation severely worsened, necessitating her admission to the regional hospital.</p><p>At the admission, the wound appeared slightly budding and suppurating, and the patient was taken to the orthopedic department for surgical excision. A pus sample was collected for microbiological analysis. The results returned the presence of Gram-negative bacilli suspected to be a Yersinia pestis, which was resistant to</p><p>aztreonam, cephalothin, ceftriaxone, chloramphenicol, and colistin. Nonetheless, the strain was susceptible to carbapenems (imipenem), aminoglycosides (gentamicin, kanamycin, tobramycin), quinolones (ciprofloxacin), and penicillin’s (ticarcillin, Amoxicillin-clavulanic acid) (see Supplementary Table). Thereafter, the patient was treated with a combination of intravenous antibiotics (clavulanic acid, Clavuject for 1 g &#215; 3/day), antalgic (Perfalgan for 1 g &#215; 3/day and Dynapar 1 amp &#215; 2/day), and anticoagulant (Lovenox 0.4 mg/day). After two weeks, she showed a positive evolution and was released from the hospital on June 1<sup>st</sup>, 2021 for home or nursing office care. She was following up for at least 4 weeks with aseptic cleaning, and from the latest news, her health condition was stable, even thought she was not completely healed. It must be stressed that results on Yersinia pestis detection should be taken with caution, due to the drastically decreasing incidence of plague in Senegal and overall in Africa since 1949 [<xref ref-type="bibr" rid="scirp.115971-ref4">4</xref>]. Since plague is a reportable disease in Senegal, an epidemiological investigation was initiated and a wound swab was collected on the day of the patient discharge and sent to Institut Pasteur de Dakar (IPD) for confirmation and further investigation. Microbiological analysis revealed Gram-negative cocobacilli. Culture on different medial (chocolate, MacConkey and bromocresol purple agars) showed smooth and rounded colonies identified as A. baumannii with API biochemical tests. Antimicrobial susceptibility testing performed by disk diffusion and automated (Vitek 2 system, bioM&#233;rieux) methods revealed resistance to penicillin’s (ticarcillin, piperacillin, ticarcillin-acid clavulanic, piperacillin-tazobactam), sulphonamides (trimethoprim-sulfamethoxazole), carbapenems (meropenem, ertapenem, imipenem), cephalosporins (cefotaxime, ceftazidime, cefepime), gentamicin, tetracyclines (tetracycline, minocycline) and fluoroquinolones (ciprofloxacin), and susceptibility to colistin, amikacin, and tobramycin (<xref ref-type="table" rid="table1">Table 1</xref>). Based on these results, we classified this clone as an XDR A. baumannii that is resistant to at least one drug from all categories except two or fewer [<xref ref-type="bibr" rid="scirp.115971-ref5">5</xref>].</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Antimicrobial susceptibility testing in XDR Acinetobacter baumannii</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >Antibiotic class</th><th align="center" valign="middle" >Antibiotics</th><th align="center" valign="middle" >value (mm)</th><th align="center" valign="middle" >value (mg/L)</th><th align="center" valign="middle" >Interpretation</th></tr></thead><tr><td align="center" valign="middle"  rowspan="4"  >Penicillin’s</td><td align="center" valign="middle" >Piperacillin-tazobactam</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >≥128</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Piperacillin</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >≥128</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Ticarcillin</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >≥128</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Ticarcillin-clavulanic acid</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >≥128</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Aminoglycosides</td><td align="center" valign="middle" >Tobramycin</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >≤1</td><td align="center" valign="middle" >S</td></tr><tr><td align="center" valign="middle" >Amikacin</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >≤2</td><td align="center" valign="middle" >S</td></tr><tr><td align="center" valign="middle" >Gentamicin</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >≥16</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Cephalosporines</td><td align="center" valign="middle" >Cefotaxime</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >NT</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Ceftazidime</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >≥64</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Cefepime</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >NT</td><td align="center" valign="middle" >R</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >Carbapenems</th><th align="center" valign="middle" >meropenem</th><th align="center" valign="middle" >6</th><th align="center" valign="middle" >≥16</th><th align="center" valign="middle" >R</th></tr></thead><tr><td align="center" valign="middle" >Imipenem</td><td align="center" valign="middle" >NT</td><td align="center" valign="middle" >≥16</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Ertapenem</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >NT</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Quinolones</td><td align="center" valign="middle" >Ciprofloxacin</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >≥4</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Sulphonamides</td><td align="center" valign="middle" >Trimethoprim-sulfamethoxazole</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >≥40</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Tetracycline</td><td align="center" valign="middle" >Minocycline</td><td align="center" valign="middle" >NT</td><td align="center" valign="middle" >≥16</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Tetracycline</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >NT</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >Miscellaneous</td><td align="center" valign="middle" >Colistin</td><td align="center" valign="middle" >NT</td><td align="center" valign="middle" >≤0.5</td><td align="center" valign="middle" >S</td></tr></tbody></table></table-wrap></table-wrap-group><p>R: resistant; S: sensitive; NT: not tested; mm: millimetre; mg/L: milligram per litre.</p></sec><sec id="s3"><title>3. Discussion</title><p>The emergence and dissemination of MDR A. baumannii are a global public health concern. A. baumannii belongs to the ESKAPE group of pathogens, which are characterized by their ability to rapidly develop resistance to numerous antibiotics. In Senegal, the epidemiology of MDR A. baumannii, including carbapenem-resistant clones, is poorly documented. Available literature shows its presence both at the community and hospital level, even though no epidemiological data on its burden is available yet [<xref ref-type="bibr" rid="scirp.115971-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.115971-ref7">7</xref>]. From our results, we cannot firmly conclude that the isolated XDR A. baumannii was the aetiological agent of the wound that the patient suffered from. It was unfortunate that the suspected Y. pestis clone initially isolated was not stored, preventing any confirmation. However, since the patient’s condition improved following the initial treatment and given that A. baumannii was isolated 13 days after admission corresponding to her day of release, we believe of a case of hospital-acquired infection, likely during wound cleaning. In Africa, the prevalence of hospital-acquired infections (HAIs) ranges from 10% to 60%, and they are the third, second and first leading causes of maternal mortality, early neonatal mortality and postoperative morbidity, respectively. HAI prevalence is estimated at 10% in Benin, 10.9% in Senegal, 12% in the Ivory Coast, and 14% in Mali [<xref ref-type="bibr" rid="scirp.115971-ref8">8</xref>]. A review that examined the incidence and prevalence of HAIs by A. baumannii in Europe revealed that this bacterium is more frequent (&gt;20%) than other common nosocomial pathogens like Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus [<xref ref-type="bibr" rid="scirp.115971-ref9">9</xref>]. A similar pattern was described in Southeast Asia [<xref ref-type="bibr" rid="scirp.115971-ref10">10</xref>], China [<xref ref-type="bibr" rid="scirp.115971-ref11">11</xref>], and Latin America [<xref ref-type="bibr" rid="scirp.115971-ref12">12</xref>], but it was different in the United States, where HAIs with Acinetobacter spp in ICUs were estimated to be only 1.1% [<xref ref-type="bibr" rid="scirp.115971-ref13">13</xref>]. Data on the burden of MDR A. baumannii infections, including carbapenem-resistant clones are very scarce in Africa. Nonetheless, available data suggest a widespread distribution of carbapenemase-producing strains with prevalence ranging from 2.3% to 67.7% in North Africa and 9% to 60% in sub-Saharan Africa [<xref ref-type="bibr" rid="scirp.115971-ref14">14</xref>]. Studies to delineate the magnitude and spread of A. baumannii infections across Africa are therefore urgently needed. To our knowledge, this study is the first reporting a potential HAI with XDR A. baumannii in Senegal. It stresses the importance to strengthening and enforcing guidelines for patient management, especially those in ICUs. Moreover, surveillance systems should be implemented to study the evolution, dynamic of transmission and biological role of important nosocomial pathogens like A. baumannii.</p></sec><sec id="s4"><title>4. Conclusion</title><p>Emergence of MDR A. baumannii in clinical settings is of critical importance. This case illustrates a potential HAI XDR A. baumannii infection in Senegal, where data on this bacterium are scarce. This stresses the need of an active surveillance of A. baumannii in LMIC hospitals as well the development and enforcement of effective guidelines for patient management.</p></sec><sec id="s5"><title>Acknowledgements</title><p>We thank the ministry of Health of Senegal and the medical staff from Ourossogui hospital for the coordination of the case investigation and intervention.</p></sec><sec id="s6"><title>Authors and Contributors</title><p>Conceptualization: CF, BSB, YD; methodology: OS, FPL; validation: CF, OS, FPL, YD; investigation: BD; original draft preparation: CF; writing-review and editing: CF, OS, FPL, BSB, YD. All authors have read and agreed to the published version of the manuscript.</p></sec><sec id="s7"><title>Ethical Approval</title><p>The authors declare that the privacy of the patient was respected according to the CIOMS rules, regarding the privacy of the data collected.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>All the authors declare no conflict of interest.</p></sec><sec id="s9"><title>Cite this paper</title><p>Fall, C., Sow, O., Ly, F.P., Diop, B., Sambe-Ba, B. and Dieye, Y. (2022) An Extensively Drug Resistant Acinetobacter baumannii from Soft Tissue Isolated in a Hospital in Senegal. Case Reports in Clinical Medicine, 11, 72-78. https://doi.org/10.4236/crcm.2022.113011</p></sec><sec id="s10"><title>Supplementary Table: Antimicrobial Susceptibility Testing in Yersinia pestis</title></sec></body><back><ref-list><title>References</title><ref id="scirp.115971-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Erbay, A., Idil, A., G&amp;ouml;zel, M.G., Mumcuo&amp;#287;lu, I. and Balaban, N. (2009) Impact of Early Appropriate Antimicrobial Therapy on Survival in Acinetobacter baumannii Bloodstream Infections. International Journal of Antimicrobial Agents, 34, 575-579. https://doi.org/10.1016/j.ijantimicag.2009.07.006</mixed-citation></ref><ref id="scirp.115971-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Tacconelli, E., et al. (2018) Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis. The Lancet Infectious Diseases, 18, 318-327.</mixed-citation></ref><ref id="scirp.115971-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Greene, C., Vadlamudi, G., Newton, D., Foxman, B. and Xi, C. (2016) The Impact of Biofilm Formation and Multidrug Resistance on Environmental Survival of Clinical and Environmental Isolates of Acinetobacter baumannii. American Journal of Infection Control, 44, e65-e71. https://doi.org/10.1016/j.ajic.2015.12.012</mixed-citation></ref><ref id="scirp.115971-ref4"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Davis</surname><given-names> D.H.S. </given-names></name>,<etal>et al</etal>. (<year>1953</year>)<article-title>Plague in Africa from 1935 to 1949</article-title><source> Bulletin of the World Health Organization</source><volume> 9</volume>,<fpage> 665</fpage>-<lpage>700</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.115971-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Magiorakos, A.-P., et al. (2012) Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance. Clinical Microbiology and Infection. European Society of Clinical Microbiology and Infectious Diseases, 18, 268-281. https://doi.org/10.1111/j.1469-0691.2011.03570.x</mixed-citation></ref><ref id="scirp.115971-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kempf, M., et al. (2012) Carbapenem Resistance and Acinetobacter baumannii in Senegal: The Paradigm of a Common Phenomenon in Natural Reservoirs. PloS ONE, 7, e39495. https://doi.org/10.1371/journal.pone.0039495</mixed-citation></ref><ref id="scirp.115971-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Diene, S.M. et al. (2013) Emergence of the OXA-23 Carbapenemase-Encoding Gene in Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Principal Hospital of Dakar, Senegal. International Journal of Infectious Diseases, 17, e209-e210. https://doi.org/10.1016/j.ijid.2012.09.007</mixed-citation></ref><ref id="scirp.115971-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Recommendations on the Fight against Nosocomial Infections Compliance in Health Facilities of Yaounde (Cameroon). International Journal of Scientific Research and Management. https://ijsrm.in/index.php/ijsrm/article/view/2301</mixed-citation></ref><ref id="scirp.115971-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ayobami, O., Willrich, N., Harder, T., Okeke, I.N., Eckmanns, T. and Markwart, R. (2019) The Incidence and Prevalence of Hospital-Acquired (Carbapenem-Resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: A Systematic Review and Meta-Analysis. Emerging Microbes &amp; Infections, 8, 1747-1759. https://doi.org/10.1080/22221751.2019.1698273</mixed-citation></ref><ref id="scirp.115971-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ling, M.L., Apisarnthanarak, A. and Madriaga, G. (2015) The Burden of Healthcare-Associated Infections in Southeast Asia: A Systematic Literature Review and Meta-Analysis. Clinical Infectious Diseases, 60, 1690-1699. https://doi.org/10.1093/cid/civ095</mixed-citation></ref><ref id="scirp.115971-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yue, D., et al. (2017) Hospital-Wide Comparison of Health Care-Associated Infection among 8 Intensive Care Units: A Retrospective Analysis for 2010-2015. American Journal of Infection Control, 45, e7-e13. https://doi.org/10.1016/j.ajic.2016.10.011</mixed-citation></ref><ref id="scirp.115971-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Luna, C.M., Rodriguez-Noriega, E., Bavestrello, L. and Guzmán-Blanco, M. (2014) Gram-Negative Infections in Adult Intensive Care Units of Latin America and the Caribbean. Critical Care Research and Practice, 2014, 480463. https://doi.org/10.1155/2014/480463</mixed-citation></ref><ref id="scirp.115971-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">McCann, E., et al. (2018) Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofy241</mixed-citation></ref><ref id="scirp.115971-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Manenzhe, R.I., Zar, H.J., Nicol, M.P. and Kaba, M. (2015) The Spread of Carbapenemase-Producing Bacteria in Africa: A Systematic Review. Journal of Antimicrobial Chemotherapy, 70, 23-40. https://doi.org/10.1093/jac/dku356</mixed-citation></ref></ref-list></back></article>